These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 25874839)
1. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Meeker AS; Herink MC; Haxby DG; Hartung DM Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839 [TBL] [Abstract][Full Text] [Related]
2. Vortioxetine for depression in adults. Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828 [TBL] [Abstract][Full Text] [Related]
3. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320 [TBL] [Abstract][Full Text] [Related]
4. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Li G; Wang X; Ma D Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232 [TBL] [Abstract][Full Text] [Related]
5. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. Berhan A; Barker A BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373 [TBL] [Abstract][Full Text] [Related]
6. Vortioxetine: a New Treatment for Major Depressive Disorder. Connolly KR; Thase ME Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430 [TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Fu J; Chen Y Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704 [TBL] [Abstract][Full Text] [Related]
8. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Citrome L Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Mahableshwarkar AR; Jacobsen PL; Chen Y Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878 [TBL] [Abstract][Full Text] [Related]
11. Vortioxetine for the treatment of depression. Pearce EF; Murphy JA Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Brignone M; Diamand F; Painchault C; Takyar S Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048 [TBL] [Abstract][Full Text] [Related]
13. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949 [TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048 [TBL] [Abstract][Full Text] [Related]
15. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600 [TBL] [Abstract][Full Text] [Related]
16. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. Baune BT; Sluth LB; Olsen CK J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488 [TBL] [Abstract][Full Text] [Related]
18. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164 [TBL] [Abstract][Full Text] [Related]
19. [Vortioxetine in the treatment of major depression]. de Bartolomeis A; Fagiolini A; Maina G Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982 [TBL] [Abstract][Full Text] [Related]
20. [Vortioxetine: a new antidepressant to treat depressive episodes]. Colle R; Corruble E Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]